17 min
Bonus Episode: A podcast exploring the DaBlaCa-13 study, chemoresection with dose-dense mitomycin C (MMC) in patients with recurrent non-muscle-invasive bladder cancer (intermediate-risk) The EMJ Podcast: Insights For Healthcare Professionals
-
- Education
Tune in for a fascinating discussion with Jørgen Bjerggaard Jensen, Department of Urology, Aarhus University, Denmark, as he explores recent breakthroughs in non-muscle-invasive bladder cancer (NMIBC) management through mitomycin C (MMC) chemoresection.
Jensen addresses the critical need to advance NMIBC management, underscoring its unique status as a disease of field cancerisation. Delving into the study’s main findings, Jensen discusses the efficacy of MMC chemoresection and the potential effectiveness in both low-grade and high-grade Ta tumours. Safety and tolerability aspects are also examined, highlighting the promise this intervention holds for patients and urologists alike.
This content was funded by medac GmbH.
Tune in for a fascinating discussion with Jørgen Bjerggaard Jensen, Department of Urology, Aarhus University, Denmark, as he explores recent breakthroughs in non-muscle-invasive bladder cancer (NMIBC) management through mitomycin C (MMC) chemoresection.
Jensen addresses the critical need to advance NMIBC management, underscoring its unique status as a disease of field cancerisation. Delving into the study’s main findings, Jensen discusses the efficacy of MMC chemoresection and the potential effectiveness in both low-grade and high-grade Ta tumours. Safety and tolerability aspects are also examined, highlighting the promise this intervention holds for patients and urologists alike.
This content was funded by medac GmbH.
17 min